Author:
Boehler Jessica F,Brown Kristy J,Beatka Margaret,Gonzalez J Patrick,Donisa Dreghici Roxana,Soustek-Kramer Meghan,McGonigle Sharon,Ganot Annie,Palmer Timothy,Lowie Caitlin,Chamberlain Jeffrey S.,Lawlor Michael W,Morris Carl A
Subject
Genetics (clinical),Neurology (clinical),Neurology,Pediatrics, Perinatology and Child Health
Reference105 articles.
1. Drugs, devices, and the FDA: part 1: an overview of approval processes for drugs;Van Norman;JACC Basic Transl Sci,2016
2. Biomarkers and surrogate markers: an FDA perspective;Katz;NeuroRx,2004
3. FDA. Table of surrogate endpoints that were the basis of drug approval or licensure. https://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure 2021;Accessed Nov 2021.
4. FDA. Accelerated Approval Program https://www.fda.gov/drugs/information-health-care-professionals-drugs/accelerated-approval-program 2020;Accessed Oct 2021.
5. Kakkis E.D. Aduhelm's accerlerated approval offers a promosing roadmap for rare neurological diseases. https://www.statnews.com/2021/07/07/accelerated-approval-aduhelm-promising-roadmap-rare-diseases/2021; Accessed Nov 2021.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献